Condition
Post Treatment.
Total Trials
1
Recruiting
0
Active
0
Completed
0
Key Insights
Highlights
Treatment Research
1 treatments under study, led by Intravenous Immunoglobulins Human Immunoglobulins G
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 80/100
Termination Rate
100.0%
1 terminated out of 1 trials
Success Rate
0.0%
-86.6% vs benchmark
Late-Stage Pipeline
100%
1 trials in Phase 3/4
Results Transparency
0%
0 of 0 completed with results
Key Signals
0
Data Visualizations
Phase Distribution
1Total
Phase 3 (1)
Trial Status
Terminated1
Clinical Trials (1)
Showing 1 of 1 trials
Showing all 1 trials
Research Network
Common Treatments
- Intravenous Immunoglobulins Human Immunoglobulins G1
Active Sponsors
- Assistance Publique - Hôpitaux de Paris1
Top Investigators
Assistance Publique - Hôpitaux de Paris
Related Conditions
- And Immunosuppressant Therapies Or After One Year1
- Anca Vasculitides Relapsing Either Under Corticosteroid1